Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) st (Q45024357)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) st	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) st (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

Philadelphia chromosome

1 reference

object named as

Philadelphia chromosome

2 August 2024

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

François Guilhot

object named as

François Guilhot

13

0 references

Hagop Kantarjian

9

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

object named as

Timothy P Hughes

11

0 references

Michele Baccarani

1

object named as

Michele Baccarani

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Jorge Eduardo Cortes

12

object named as

Jorge E Cortes

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Jerald P Radich

10

object named as

Jerald P Radich

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

3

object named as

Susan Branford

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

7

object named as

Manisha Mone

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

author name string

Dong-Wook Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Fabrizio Pane

5

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Lidia Mongay

6

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Christine-Elke Ortmann

8

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

publication date

1 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

99

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

616-624

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Identifiers

10.1007/S12185-014-1566-2

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Dimensions Publication ID

0 references

release_42fkvj3s5bfu7jr4lqh6dryew4

1 reference

https://api.fatcat.wiki/v0/release/42fkvj3s5bfu7jr4lqh6dryew4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45024357&oldid=2218892586"